08D Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Mirum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.00 |
| 52 Week High | US$46.80 |
| 52 Week Low | US$21.80 |
| Beta | 0.98 |
| 1 Month Change | 12.82% |
| 3 Month Change | 22.91% |
| 1 Year Change | 81.82% |
| 3 Year Change | 185.49% |
| 5 Year Change | n/a |
| Change since IPO | 178.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 08D | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -2.8% | 2.7% |
| 1Y | 81.8% | -5.9% | 13.1% |
Return vs Industry: 08D exceeded the German Biotechs industry which returned -5.3% over the past year.
Return vs Market: 08D exceeded the German Market which returned 11.9% over the past year.
Price Volatility
| 08D volatility | |
|---|---|
| 08D Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 08D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 08D's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 311 | Chris Peetz | www.mirumpharma.com |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
Mirum Pharmaceuticals, Inc. Fundamentals Summary
| 08D fundamental statistics | |
|---|---|
| Market cap | €2.15b |
| Earnings (TTM) | -€95.81m |
| Revenue (TTM) | €294.72m |
7.6x
P/S Ratio-23.4x
P/E RatioIs 08D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 08D income statement (TTM) | |
|---|---|
| Revenue | US$307.03m |
| Cost of Revenue | US$83.88m |
| Gross Profit | US$223.15m |
| Other Expenses | US$322.96m |
| Earnings | -US$99.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 72.68% |
| Net Profit Margin | -32.51% |
| Debt/Equity Ratio | 132.6% |
How did 08D perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 19:47 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mirum Pharmaceuticals, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |